INS and type 2 diabetes mellitus: Furthermore, a few small, short-term randomized controlled trials have demonstrated that the addition of HCQ (at a dose ranging from 400 to 600 mg/day) to sulfonylureas or insulin therapy in T2D patients led to significant reductions in HbA1c values without increasing the risk of hypoglycemia [81,82,83].